BioCentury
ARTICLE | Financial News

Aridis amends IPO

August 10, 2018 4:27 PM UTC

Immunotherapy company Aridis Pharmaceuticals Inc. (San Jose, Calif.) amended its NASDAQ IPO on Aug. 6 and now plans to sell 2 million shares at $13-$15. The offering is being underwritten by Cantor Fitzgerald, Maxim, Laidlaw, Northland and Seaport. On July 18, the company filed to raise up to $34.5 million.

At the $14 midpoint of its proposed range, Aridis would raise $28 million and be valued at $109.3 million...

BCIQ Company Profiles

Aridis Pharmaceuticals Inc.